Click here
Thursday 20 June 2013 Register   Login
Search 
  
You are here:
Home
News
Latest issue
Subscribe
Email bulletin
Suppliers Guide
Advertise
Contact us
New neurology product
Complete an online survey about new products for stroke prevention and receive €225. Click here
LATEST ISSUE
Medication safety, improving patient outcomes, ‘smart’ pump implementation, monitoring of cleanrooms, aclidium bromide in the treatment of COPD, managing pain in renal impairment, labelling, cardiovascular disease risk management, RTU/RTA injections, preventing ischaemic stroke, topical anaesthetics in dermatology, High 5s
Industry News
Wednesday 19 June
Jakavi® impacted an underlying mechanism of disease
Novartis has announced results from a Phase III three-year follow-up study that showed Jakavi® (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy.
Monday 17 June
Nanobiotix receives approval from ANSM
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has announced that its lead compound NBTXR3 has received authorisation from the French Medicine Agency, ANSM,(1) to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment centre. This represents a second indication for NBTXR3 which is also in clinical trials for soft tissue sarcoma.
Tuesday 4 June
Nintedanib* plus chemotherapy
The LUME-Lung 1 Phase III clinical trial results showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor, extended life by 2.3 months for non-small cell lung cancer (NSCLC) adenocarcinoma patients when added to docetaxel, versus placebo plus docetaxel.
See all Industry News »
CENTRAL NERVOUS SYSTEM
Rufinamide in Lennox-Gastaut syndrome
Wednesday 17 October 2012
Rufinamide is an anti-epileptic drug that received marketing authorisation as adjunctive therapy in Lennox-Gastaut syndrome (LGS) from the European commission in January 2007 and the FDA in November 2008. It has a different mode of action from other anti-epileptic drugs: it modulates the frequency of sodium-dependent neuronal action potentials, although the precise mechanism is yet to be determined. The Cmax is approximately six hours and the half-life is six-to-ten hours in healthy volunteers. Sodium valproate may decrease the clearance. It is not strongly protein bound. Although licensed only for the treatment of LGS, efficacy has also been demonstrated in other epilepsy syndromes and seizure types, notably partial seizures.
MRI findings dispute blood flow and MS correlation
Wednesday 22 August 2012
While researchers have speculated that changes in brain blood flow due to vein abnormalities contribute to multiple sclerosis (MS) disease severity, a study published online Aug. 21 in Radiology has demonstrated this may not be the case as these abnormalities were shown not to be specific to MS.
ONCOLOGY
US FDA approves REVLIMID
Thursday 6 June 2013
Celgene Corporation (NASDAQ: CELG) has announced the US Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for REVLIMID® (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
Superiority of afatinib over comparator chemotherapy
Tuesday 4 June 2013
Data from Boehringer Ingelheim’s LUX-Lung 6 trial, presented at the official American Society of Clinical Oncology (ASCO) Annual Conference, demonstrate that patients treated with the novel, investigational compound afatinib* lived for almost one year before their tumour started to grow again, compared to less than half a year for those on standard chemotherapy (gemcitabine/cisplatin).
Roundtable

 meeting

Safe preparation and administration of cytotoxics

Hospital Pharmacy Europe recently hosted a meeting of a panel of European expert pharmacists in Frankfurt, Germany to review the safe preparation and administration of cytotoxic drugs. Topics included hazards of cytotoxic drug preparation, safety assurance requirements and the likely impact of the European Resolution CM/ResAP(2011)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients.

To download the article, click here


How to implement ‘smart’ pump technology successfully to help reduce IV medication errors

The purpose of this advisory board, recently held in Amsterdam, was to investigate the relatively slow uptake of ‘smart’ pumps in Europe and especially the use of drug libraries. Key points discussed included: administration of injections, use of ‘smart’ pumps, value for money, barriers to use and improved safety.

To download the article, click here

Supplements

HPE supplements are created to provide readers with dedicated resources and materials for specific areas of hospital pharmacy. Click on the images below to access the latest supplements:
CareFusion Handbook, BD Medical Handbook, Hospital Vascular Access Europe and Hospital Oncology & Haematology Europe
 
CareFusion+Handbk BD+Handbk
 
HVAE HOHE+3+FC

Advertisement Features

© Campden Publishing Limited 2013
Site Map | Accessibility | Terms & Conditions | Privacy Policy | Contacts
Campden Publishing Ltd., 140 London Wall London EC2Y 5DN, is a company registered in the United Kingdom with Reg. No. 2147432
www.campden.com

Web design, hosting and programming by ModeZero